Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB-205 |
Synonyms | |
Therapy Description |
AB-205 consists of engineered CD31 (PECAM-1) positive human umbilical vein-derived endothelial cells, which potentially improve transplant engraftment and enhance recovery of blood cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB-205 | AB205|AB 205|engineered HUVEC AB-205 | AB-205 consists of engineered CD31 (PECAM-1) positive human umbilical vein-derived endothelial cells, which potentially improve transplant engraftment and enhance recovery of blood cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05181540 | Phase III | AB-205 | A Phase 3 Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) | Terminated | USA | 0 |
NCT03925935 | Phase I | AB-205 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | Completed | USA | 0 |